Fungal infections in cirrhotic patients have emerged as a life-threatening problem in the era of abundant use of broad spectrum antibiotics. The diagnosis of invasive fungal infections is often delayed with poor prognosis. Herein, we report two cases of fungemia in patients who underwent therapeutic EVO for gastric variceal bleeding. Both patients developed sustained high fever after repeated EVO procedures while on prophylactic antibiotic use. In both patients, blood cultures revealed yeast, and they were finally diagnosed with *Candida* infection. *Candida* is a common member of the intestinal flora; however, it can cause invasive infection with consequent poor prognosis in cirrhotic patients. The route of *Candida* invasion is unclear; however, repeated EVO may predispose patients to *Candida* infection, particularly those who are in the end stage of liver disease and receiving prophylactic antibiotics. Our cases highlight that repeated invasive procedures can increase the risk of fungal infections, and fungemia should be considered in the differential diagnosis of post-EVO fever.

**Key Words:** Fungemia, endoscopic variceal obturation, fever, liver cirrhosis

**INTRODUCTION**

Fungal infections in cirrhotic patients have emerged as a life-threatening problem in the era of abundant use of broad spectrum antibiotics. The diagnosis of invasive fungal infections is often delayed with poor prognosis. Herein, we report two cases of fungemia in patients who were treated with therapeutic endoscopic variceal obturation (EVO) for acute gastric variceal bleeding.

**CASE REPORT**

**Case 1**

A 55-year-old man with a history of alcohol-related liver cirrhosis and type 2 diabetes mellitus was admitted to the emergency room (ER) with hematemesis. He reported a 30-year history of alcohol consumption (>150 g/day) and showed a low-grade fever (38.1°C). Blood culture was done. Viral marker for hepatitis B or C was all negative, and abnormal laboratory data showed white blood cell count of 11.4×10^9/L, hemoglobin (Hb) of 12.4 g/dL, platelets of 34×10^9/L, International Normalized Ratio (INR) of 1.5, albumin of 3.1 g/dL, total bilirubin of 7.3 mg/dL, and glycated hemoglobin (HbA1c) of 10.6%.

Abdominal computed tomography (CT) revealed liver cirrhosis without gastrorenal shunt. Child-Pugh Score (CPS) was classified as class C with a score of 10, and the model for end-stage liver disease (MELD) score was 18. Gastrofibroscopy revealed a large gastroesophageal varix with red-color sign on the posterior fundic wall (Fig. 1A). Three injections of a cyanoacrylate (0.5 mL) and lipiodol (0.5 mL) mixture [1 mL, 1 mL, and 0.5 mL (total 2.5 mL)] were done (Fig. 1B). Intravenous (IV) terlipressin, proton pump inhibitor, and prophylactic 3rd generation cephalosporin (ceftriaxone 2 g/day) were administered. Follow-up abdominopelvic CT revealed cyanoacrylate-lipiodol mixture in the varices without distant migration. After 2
days, additional EVO procedure was done for secondary prophylaxis with two injections (1 mL and 0.5 mL). From the following day, the subject developed high fever (38.7°C) that lasted for 5 days (Fig. 3A). Follow-up investigations including urinalysis, sputum cultures, chest radiography, and CT were unremarkable. Antibiotics were stepped up to piperacillin/tazobactam, and blood cultures were repeated every 1–2 days. The blood culture conducted at ER visit was negative; however, yeast was detected on the 6th day of blood culture conducted since the day of high fever, and yeast was also detected in all subsequent follow-up cultures. Fever was immediately subsided, and the subject showed clinical improvement to IV fluconazole. Yeast was finally reported as *Candida glabrata*. We discontinued piperacillin/tazobactam. Fluconazole was switched to caspofungin for more than 14 days after negative conversion in the blood culture. The subject was discharged with complete improvement of symptoms.

**Case 2**

A 53-year-old woman with a history of alcoholic liver cirrhosis
presented with melena and hematemesis. She reported a 30-year history of alcohol consumption (300 g of alcohol/week). She was alert and showed blood pressure of 81/53 mm Hg with heart rate of 75 bpm and hypothermia (35.4°C). Blood culture was immediately done. Viral marker for hepatitis B or C was all negative, and abnormal laboratory data showed in Hb of 7.6 g/dL, platelets of 86×10^9/L, total bilirubin of 4.1 mg/dL, albumin of 2.8 g/dL, and INR of 1.47. Abdominopelvic CT revealed liver cirrhosis with gastrorenal shunt. CPS was classified as class B with a score of 8, and MELD score was 16. Endoscopy revealed a large isolated gastric varix on the posterior fundic wall (Fig. 2A). Four injections of a cyanoacrylate (0.5 mL) and lipiodol (0.5 mL) mixture were done [1 mL, 1 mL, 0.5 mL, and 1 mL (total 3.5 mL)] (Fig. 2B). IV terlipressin, 2 g/day of ceftriaxone, and PPI were administered to the subject. Post-EVO abdominopelvic CT revealed cyanoacrylate-lipiodol mixture deposition the posterior fundic wall without evidence of embolism. Two additional EVO for secondary prophylaxis were done on day 2 and day 6 (one injection of 0.5 mL during the 1st session, two injections of 1 mL and 0.5 mL during the 2nd session). We attempted a plug-assisted retrograde transvenous obliteration procedure for the complete prophylactic treatment, but it was unsuccessful due to the huge diameter of gastrorenal shunt. On the third day after the 3rd EVO procedure, the subject developed high fever (38.8°C) (Fig. 3B). The blood culture conducted at ER visit had been reported as negative.

![Clinical course of the patient. A: Horizontal axis indicated the timeline of case 1 including EVO dates, period of antibiotic or antifungal agents use, and identified culture period. Vertical axis indicated fever pattern of case 1. B: Horizontal axis indicated the timeline of case 2 including EVO dates, period of antibiotic or antifungal agents use, and identified culture period. Vertical axis indicated fever pattern of case 2. EVO, endoscopic variceal obturation; PARTO, plug-assisted retrograde transvenous obliteration.](https://doi.org/10.3349/ymj.2021.62.2.182)
Neutropenia was gradually progressed down to 0.63×10⁹/L during the high fever. We switched antibiotics from ceftriaxone to levofloxacin with the concern of drug fever or cytopenia. One pair of blood cultures revealed yeast on the seventh day of high fever (Fig. 3B). We immediately initiated IV fluconazole. Fever subsided after 3 days of fluconazole administration, and the causative organism was *Candida albicans*. During fluconazole administration, the subject received two additional EVO procedures for recurrent variceal bleeding (two injections of 0.5 mL during both sessions), without fever. Fluconazole was maintained for 15 days, and the subject was discharged without any symptoms.

We obtained informed consent from the patients regarding the reporting and publication of this case report.

**DISCUSSION**

Transient fever occurs in 90% of patients after EVO.5,5 Possible causes include abscess, distant embolism,4 and bacteremia.5,5,7 Isolated post-EVO bacteremia has been reported in 0–50% of cases,6 which can be caused by bacterial invasion through contaminated needle tips or by bacterial migration through a cyanoacrylate plug.5,9 Liberal use of prophylactic antibiotics exposes patients to gut dysbiosis and consequent bacterial or fungal infections.5,10 In particular, decompensated cirrhotic patients are vulnerable to fungal infection due to liberal use of PPI, and a few cases of fungal infections in end-stage liver disease were reported to be related to prophylactic antibiotics usage in patients with variceal bleeding.11 The prevalence of fungal infections in patients with cirrhosis were reported to be 4–20%,1,12 and mortality rates as high as 30–78%.1,13,12 However, there has been little evidence for prophylactic antifungal treatment, and it is still not recommended.

Our two patients had high risks of opportunistic fungal infection such as excessive alcohol use, pancytopenia, and poorly controlled diabetes mellitus. Both cases had poor liver function with large size varix, and complete eradication of the feeding vessel was thought to be helpful in reducing the rebleeding risk.15,16 For complete obliteration of a large varix, multiple injections of cyanoacrylate are required to restrict the amount of cyanoacrylate to less than 1.0 mL per injection and 3.0 mL for each session, considering the risks of embolism or ulcer formation.5,17,18 Since cyanoacrylate causes acute endovascular necrosis and increased vascular permeability by foreign body reaction, repeated punctures with short intervals could increase the risk of microbial invasion and subsequent blood stream infection,19 which may contribute to candidemia. In particular, the risk of fungal infection may increase at the following EVO session due to the greater suppression of normal intestinal flora resulting from longer use of antibiotics and PPIs.

In both patients, there were no other signs indicating candida infection on urine and sputum cultures or chest x-ray. Both subjects did not have an intravascular or Foley catheter, and there were no signs of esophageal or oral candidiasis in gastrofibroscopy. Therefore, we considered the possibility of blood stream infection of candida by repeated punctures at the EVO site. Focal invasion of candida through the ulcer occurring at the EVO site may cause candidemia, but it is known that the ulcer formation after EVO usually occurs about 1–3 months after the procedure.20 Therefore, the possibility of candida invasion through the ulcer of EVO site was considered to be low. Indeed, in both cases, ulcers at the EVO site were not observed in gastrofibroscopy until before candidemia was developed. Additionally, the whole stomach was evaluated again to exclude the possibility of other bleeding focus in every EVO procedure, and there were no findings that could be regarded as gastric candidiasis, such as multiple ulcers or ulcers with dirty margins. Therefore, we could exclude gastric candidiasis as the cause of candidemia.

In conclusion, fungemia should be carefully considered in post-EVO fever, especially in patients with high risks of opportunistic infection. The number of EVO sessions for secondary prophylaxis should be minimized in patients with liver cirrhosis.

**ACKNOWLEDGEMENTS**

This study was supported by a National Research Foundation of Korea grant from the Korean government (the Ministry of Education, Science and Technology, 2018R1D1A1B07048487).

**AUTHOR CONTRIBUTIONS**

Conceptualization: Eileen L. Yoon. Data curation: Eileen L. Yoon. Funding acquisition: Eileen L. Yoon. Investigation: Soo In Choi. Resources: Eileen L. Yoon. Supervision: Eileen L. Yoon. Visualization: Soo In Choi. Writing—original draft: Soo In Choi. Writing—review & editing: Soo In Choi and Eileen L. Yoon. Approval of final manuscript: all authors.

**ORCID iDs**

Soo In Choi https://orcid.org/0000-0001-6156-5898
Eileen L. Yoon https://orcid.org/0000-0003-0474-048X

**REFERENCES**

1. Bajaj JS, Reddy RK, Tandon P, Wong F, Kamath PS, Biggins SW, et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am J Gastroenterol 2018; 113:556-63.
2. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol 2014;61:1385-96.
3. Lahmer T, Messer M, Mayr U, Saugel B, Noe S, Schultheiss C, et al. Fungal “colonisation” is associated with increased mortality in medical intensive care unit patients with liver cirrhosis. Mycopathologia 2015;179:63-71.
4. Reuken PA, Bruns T, Zimmer B, Michael A, Brunkhorst FM, Pletz MW, et al. Recurrent fever and bacteraemia after endoscopic variceal haemostasis with cyanoacrylate: a case report. Infection 2012;40:351-3.

5. Wahl P, Lammer F, Conen D, Schlumpf R, Bock A. Septic complications after injection of N-butyl-2-cyanoacrylate: report of two cases and review. Gastrointest Endosc 2004;59:911-6.

6. Hwang SS, Kim HH, Park SH, Kim SE, Jung JI, Ahn BY, et al. N-butyl-2-cyanoacrylate pulmonary embolism after endoscopic injection sclerotherapy for gastric variceal bleeding. J Comput Assist Tomogr 2001;25:16-22.

7. Rerknimitr R, Chanyaswad J, Kongkam P, Kullavanijaya P. Risk of bacteremia in bleeding and nonbleeding gastric varices after endoscopic injection of cyanoacrylate. Endoscopy 2008;40:644-9.

8. Ho H, Zuckerman MJ, Wassem C. A prospective controlled study of the risk of bacteremia in emergency sclerotherapy of esophageal varices. Gastroenterology 1991;101:1642-8.

9. Chang YL, Park JJ, Joo MK, Lee BJ, Yun JW, Yoon DW, et al. Long-term outcomes of prophylactic endoscopic histoacryl injection for gastric varices with a high risk of bleeding. Dig Dis Sci 2010;55:2391-7.

10. Bajaj JS, Liu EI, Kheradman R, Fagan A, Heuman DM, White M, et al. Fungal dysbiosis in cirrhosis. Gut 2018;67:1146-54.

11. Hassan EA, Abd El-Rehim AS, Hassany SM, Ahmed AO, Elsherbiny NM, Mohammed MH. Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion. Int J Infect Dis 2014;23:69-74.

12. Fernández J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 2018;67:1870-80.

13. Lee HA, Goh HG, Kim TH, Lee YS, Suh SJ, Jung YK, et al. Evaluation of treatment response after endoscopic variceal obturation with abdominal computed tomography. Gut Liver 2020;14:117-24.

14. Seewald S, Siram PV, Naga M, Fennerty MB, Boyer J, Oberli F, et al. Cyanoacrylate glue in gastric variceal bleeding. Endoscopy 2002;34:926-32.

15. Lee YT, Chan FK, Ng EK, Leung VK, Law KB, Yung MY, et al. EUS-guided injection of cyanoacrylate for bleeding gastric varices. Gastrointest Endosc 2000;52:168-74.

16. Lee HA, Chang JM, Goh HG, Kim TH, Lee YS, Suh SJ, et al. Prognosis of patients with gastric variceal bleeding after endoscopic variceal obturation according to the type of varices. Eur J Gastroenterol Hepatol 2019;31:211-7.

17. Jang JY. Prevention and management of gastroesophageal varices. Korean J Med 2008;75:6-14.

18. Soehendra N, Grimm H, Nam VC, Berger B. N-butyl-2-cyanoacrylate: a supplement to endoscopic sclerotherapy. Endoscopy 1987;19:221-4.

19. Yan L, Yang C, Tang J. Disruption of the intestinal mucosal barrier in Candida albicans infections. Microbiol Res 2013;168:389-95.

20. Cheng LE, Wang ZQ, Li CZ, Cai FC, Huang QY, Linghu EQ, et al. Treatment of gastric varices by endoscopic sclerotherapy using butyl cyanoacrylate: 10 years’ experience of 635 cases. Chin Med J (Engl) 2007;120:2081-5.